Global digital pathology systems market analysis and insights

The global Digital Pathology Systems market estimated at US$963.4 million in the year 2024, is projected to reach US$2.85 billion by 2030, driven by the unprecedented shift to remote workflows for pathologists.

Pathology is the mechanism that propels healthcare towards a better understanding of diseases. Digital pathology model will be the mainstream in the future. The field of digital pathology is rapidly expanding around the world. A digital pathologist will make a diagnosis by interacting with images on computer screens and performing quantitative analysis instead of using traditional microscopy.

The fourth generation of virtual slide telepathology systems, known as virtual microscopy and Whole-Slide Imaging (WSI), has enabled image data storage and rapid dissemination in pathology and other biomedical fields. They have the potential to make pathologists’ jobs more creative and data-driven, while also allowing patients to receive faster and more accurate diagnoses. Much of this growth is being driven by increasing adoption of the technology as scientists become more aware of its benefits, as well as recent technological advancements that have recently enhanced digital pathology’s offering and made it more affordable and accessible.

Digital pathology is predicted to develop in the future due to advancements in specialized technologies such as computerization, digital imaging, numerous fiber-optic communications and robotic light microscopy. Digital microarrays are one technology that has gotten a lot of attention recently.

Artificial Intelligence (AI) will become increasingly integrated into digital pathology in the future. For now, most of the current research is focused on using AI to improve digital pathology software. AI is assisting in the development of digital pathology by improving digital picture analysis and by allowing it to interface with other data sources, resulting in a more comprehensive data set and, as a result, more accurate diagnoses.

Digital pathology systems market regional insights

North American digital pathology systems market is expected to grow significantly over the forecast period 2024-2030. This growth can be attributed to the increasing adoption of telepathology, advancements in AI and machine learning, rising prevalence of cancer, and a growing demand for efficient diagnostic tools and personalized medicine. United States contributed around 79% of the total North American digital pathology systems market, with a market size of US$408.6 million in 2024. Among the other noteworthy geographic markets are Canada and Mexico, each forecast to grow at 11.3% and 9.8% respectively over the forecast period.

The Asia-Pacific digital pathology systems market is anticipated to witness an upsurge owing to the rapid advancements in healthcare infrastructure, increasing investments in medical technology and rising prevalence of chronic diseases in the region. Also, the rising adoption of AI-driven diagnostic tools across developing countries such as China and India is expected to drive the demand for digital pathology systems over the forecast period. China is expected to dominate the Asia-Pacific market and reach a market size of US$322.4 million by 2030.

Within Europe, Germany, France, Italy and the U.K. are the key countries responsible for the significant growth of the regional market. Germany is expected to grow at a fastest CAGR of 11.9% over the forecast period.

Meanwhile, the Middle East & Africa is expected to show limited growth due to the strong presence of under-developed countries in Africa who are still struggling to meet technology standards. However, any growth that the region experiences is expected to come from developing Middle Eastern nations such as Qatar, U.A.E, and Oman due to a similar growth pattern as the Asia Pacific.

Key players

Key players profiled in the report include 3DHISTECH Ltd.; A. Menarini Diagnostics Srl; Aiforia; Apollo Enterprise Imaging Corporation; Barco NV; Cerner Corporation; Danaher Corporation; Euromex Microscopen BV; GE Healthcare; Indica Labs, Inc.; Inspirata, Inc.; Koninklijke Philips N.V.; Leica Biosystems; MD Biosciences, Inc.; Mikroscan Technologies, Inc.; Nikon Instruments, Inc.; NovoPath; Olympus; OptraScan; Orbit Image Analysis; Proscia; Roche; Sectra and ZEISS, among others.

Competitive landscape

July 11, 2024 – NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, announced that it has raised $22.5 million in Series B financing. Led by DigitalDx Ventures, with notable investors including the Labcorp Venture Fund and Kompass Kapital Management, this oversubscribed funding round will be used to drive the commercialization of at-home diagnostic tests, continue developing new diagnostic innovations, expand the pipeline of tests, and support strategic hiring initiatives.

June 21, 2024 – bioMérieux, a world leader in in-vitro diagnostics, announced that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

As part of its commitment to combat sepsis and antimicrobial resistance (AMR), in 2022 bioMérieux acquired Specific Diagnostics, a U.S. based company that has developed an AST system now called VITEK® REVEAL™. The instrument seamlessly integrates into bioMérieux’s unique and comprehensive portfolio of diagnostic solutions to address bloodstream infections and sepsis.

Global digital pathology systems market scope

• By component
  • Hardware
  • Software
  • Services

• By type
  • Anatomical pathology
  • Genetic pathology
  • Hematology and clinical pathology
  • Immunopathology
  • Chemical pathology
  • Neuropathology systems
  • Veterinary pathology systems
  • Others

• By disease/disorder
  • Cancer testing
  • Cardiovascular diseases
  • Neurological disorders
  • Infectious disease
  • Autoimmune diseases
  • Gastrointestinal disorders
  • Respiratory disorders
  • Dermatological disorders
  • Genetic diseases/disorders
  • Others

• By end use
  • Pharmaceutical and biotech companies
  • Hospitals and clinic
  • Diagnostic laboratories
  • Academic and research institutions
  • Contract research organizations (CROs)
  • Others

• By region
  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East and Africa

The research report  provides a comprehensive review of market trends, market growth drivers, PEST Analysis, Market growth inhibitors, and strategic industry activities and SWOT Analysis of key players in the market.

The report provides market estimates and forecast for geographic markets such as the North America (US, Canada, Mexico and Rest of North America), South America (Brazil, Argentina and Rest of South America), Europe (Germany, France, U.K., Russia, Italy, Spain, Sweden, Netherlands, Poland, Austria, Norway, Switzerland, Denmark and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Taiwan, India, Australia and Rest of Asia-Pacific), Middle East (Iran, Turkey, Kuwait, UAE, Israel and Rest of Middle East) & Africa.